1.76
-0.03999996(-2.22%)
Currency In USD
| Previous Close | 1.8 |
| Open | 1.8 |
| Day High | 1.8 |
| Day Low | 1.73 |
| 52-Week High | 3.83 |
| 52-Week Low | 0.22 |
| Volume | 935,242 |
| Average Volume | 1.97M |
| Market Cap | 129.5M |
| PE | -3.74 |
| EPS | -0.47 |
| Moving Average 50 Days | 1.62 |
| Moving Average 200 Days | 0.98 |
| Change | -0.04 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $137.82 as of December 05, 2025 at a share price of $1.76. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $659.18 as of December 05, 2025 at a share price of $1.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire Inc.
Dec 03, 2025 12:30 PM GMT
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage comp
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire Inc.
Dec 01, 2025 12:30 PM GMT
- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting -- Actively Evaluating Strategy Across DLB and Alzheimer’s Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or C
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2025 9:01 PM GMT
PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company’s president and CEO, Lis